Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Nat Med. 2022 Mar 21;28(4):814–822. doi: 10.1038/s41591-022-01714-5

Fig. 2. Plasma steroid metabolite associations in EPIC-Norfolk cohort and Mass General Brigham Biobank (MGBB)-Asthma cohort.

Fig. 2.

A. Plasma metabolites significantly associated with asthma in the EPIC-Norfolk cohort and replicated in the MGBB-Asthma cohort (n=17 metabolites). The dotted line indicates the cut off for odds ratio (OR) < or >1 for direction of effect. Metabolite names with an asterisk * indicate that the metabolite has not been officially confirmed based on a standard. B. Steroid metabolite associations between asthma cases and controls; asthma cases with ICS treatment and controls; asthma cases not treated with ICS and controls; and asthma cases with ICS treatment and not treated with ICS in the MGBB-Asthma cohort. The dotted line indicates the cut off for OR< or >1 for direction of effect. Individual values shown for each metabolite as odds ratios along with their lower and upper 95% confidence intervals in A and B. The legend key color shows the sub-pathway they belong to (A, B). Generalized linear model was used to compare groups (A, B); Statistical significance was determined using a bonferroni threshold and false discovery rate of 0.05 (A, B).

Abbreviations: Ast, asthma cases; ICS, inhaled corticosteroids